Trial Outcomes & Findings for A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia (NCT NCT01614899)

NCT ID: NCT01614899

Last Updated: 2022-04-12

Results Overview

The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

457 participants

Primary outcome timeframe

Baseline and 6 week

Results posted on

2022-04-12

Participant Flow

Participant milestones

Participant milestones
Measure
SM-13496 (Lurasidone HCl) 40mg
SM-13496 40 mg was administered orally once daily.
SM-13496 (Lurasidone HCl) 80mg
SM-13496 80 mg was administered orally once daily.
Placebo
Placebo was administered orally once daily.
Overall Study
STARTED
150
155
152
Overall Study
COMPLETED
106
116
110
Overall Study
NOT COMPLETED
44
39
42

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
SM-13496 (Lurasidone HCl) 40mg
n=145 Participants
SM-13496 40 mg was administered orally once daily.
SM-13496 (Lurasidone HCl) 80mg
n=152 Participants
SM-13496 80 mg was administered orally once daily.
Placebo
n=142 Participants
Placebo was administered orally once daily.
Total
n=439 Participants
Total of all reporting groups
Age, Continuous
42.0 years
STANDARD_DEVIATION 13.1 • n=99 Participants
43.6 years
STANDARD_DEVIATION 13.9 • n=107 Participants
42.9 years
STANDARD_DEVIATION 13.5 • n=206 Participants
42.9 years
STANDARD_DEVIATION 13.5 • n=7 Participants
Sex: Female, Male
Female
65 Participants
n=99 Participants
73 Participants
n=107 Participants
58 Participants
n=206 Participants
196 Participants
n=7 Participants
Sex: Female, Male
Male
80 Participants
n=99 Participants
79 Participants
n=107 Participants
84 Participants
n=206 Participants
243 Participants
n=7 Participants
Region of Enrollment
Japan
62 participants
n=99 Participants
66 participants
n=107 Participants
60 participants
n=206 Participants
188 participants
n=7 Participants
Region of Enrollment
Taiwan
19 participants
n=99 Participants
21 participants
n=107 Participants
19 participants
n=206 Participants
59 participants
n=7 Participants
Region of Enrollment
Korea, Republic of
43 participants
n=99 Participants
42 participants
n=107 Participants
43 participants
n=206 Participants
128 participants
n=7 Participants
Region of Enrollment
Malaysia
21 participants
n=99 Participants
23 participants
n=107 Participants
20 participants
n=206 Participants
64 participants
n=7 Participants

PRIMARY outcome

Timeframe: Baseline and 6 week

Population: mITT (modified intent-to-treat) population

The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

Outcome measures

Outcome measures
Measure
SM-13496 (Lurasidone HCl) 40mg
n=145 Participants
SM-13496 40 mg was administered orally once daily.
SM-13496 (Lurasidone HCl) 80mg
n=152 Participants
SM-13496 80 mg was administered orally once daily.
Placebo
n=142 Participants
Placebo was administered orally once daily.
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6
-17.9 units on a scale
Standard Deviation 1.72
-17.3 units on a scale
Standard Deviation 1.67
-13.1 units on a scale
Standard Deviation 1.72

SECONDARY outcome

Timeframe: Baseline and 6 weeks

Population: mITT (modified intent-to-treat) population

CGI-S is a clinician-rated assessment of the participant's current disease state on a 7-point scale, where a higher score is associated with greater severity of the disease. The change from baseline in CGI-S score (repeated measures) at each visit during the treatment phase is presented for the mITT population

Outcome measures

Outcome measures
Measure
SM-13496 (Lurasidone HCl) 40mg
n=140 Participants
SM-13496 40 mg was administered orally once daily.
SM-13496 (Lurasidone HCl) 80mg
n=150 Participants
SM-13496 80 mg was administered orally once daily.
Placebo
n=138 Participants
Placebo was administered orally once daily.
Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 6
-0.86 units on a scale
Standard Deviation 0.100
-0.97 units on a scale
Standard Deviation 0.097
-0.79 units on a scale
Standard Deviation 0.101

SECONDARY outcome

Timeframe: Baseline and 6 weeks

Population: mITT (modified intent-to-treat) population

The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.

Outcome measures

Outcome measures
Measure
SM-13496 (Lurasidone HCl) 40mg
n=145 Participants
SM-13496 40 mg was administered orally once daily.
SM-13496 (Lurasidone HCl) 80mg
n=152 Participants
SM-13496 80 mg was administered orally once daily.
Placebo
n=142 Participants
Placebo was administered orally once daily.
Change From Baseline in PANSS Positive Subscale Scores at Week 6
-5.4 units on a scale
Standard Deviation 0.54
-6.2 units on a scale
Standard Deviation 0.52
-4.2 units on a scale
Standard Deviation 0.54

SECONDARY outcome

Timeframe: Baseline and 6 weeks

Population: mITT (modified intent-to-treat) population

The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.

Outcome measures

Outcome measures
Measure
SM-13496 (Lurasidone HCl) 40mg
n=145 Participants
SM-13496 40 mg was administered orally once daily.
SM-13496 (Lurasidone HCl) 80mg
n=152 Participants
SM-13496 80 mg was administered orally once daily.
Placebo
n=142 Participants
Placebo was administered orally once daily.
Change From Baseline in PANSS Negative Subscale Scores at Week 6
-3.9 units on a scale
Standard Deviation 0.46
-3.4 units on a scale
Standard Deviation 0.45
-2.9 units on a scale
Standard Deviation 0.46

SECONDARY outcome

Timeframe: Baseline and 6 weeks

Population: mITT (modified intent-to-treat) population

The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.

Outcome measures

Outcome measures
Measure
SM-13496 (Lurasidone HCl) 40mg
n=145 Participants
SM-13496 40 mg was administered orally once daily.
SM-13496 (Lurasidone HCl) 80mg
n=152 Participants
SM-13496 80 mg was administered orally once daily.
Placebo
n=142 Participants
Placebo was administered orally once daily.
Change From Baseline in PANSS General Psychopathology Subscale Scores at Week 6
-8.8 units on a scale
Standard Error 0.85
-7.9 units on a scale
Standard Error 0.83
-6.3 units on a scale
Standard Error 0.85

SECONDARY outcome

Timeframe: From Baseline to 6 weeks

Population: Safety population defined as subjects who receive at least one dose of the study drug in the treatment phase.

Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a patient treated with a medicinal (investigational) product and which did not necessarily have a causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as adverse events with a start date on or after the date of the first dose through the end of follow-up, or adverse events occurring before the date of first dose and worsening during the treatment or follow-up period.

Outcome measures

Outcome measures
Measure
SM-13496 (Lurasidone HCl) 40mg
n=150 Participants
SM-13496 40 mg was administered orally once daily.
SM-13496 (Lurasidone HCl) 80mg
n=154 Participants
SM-13496 80 mg was administered orally once daily.
Placebo
n=151 Participants
Placebo was administered orally once daily.
Proportion of Participants With Treatment-emergent Adverse Events (TEAEs)
103 Participants
107 Participants
97 Participants

SECONDARY outcome

Timeframe: From Baseline to 6 weeks

Population: Safety population defined as subjects who receive at least one dose of the study drug in the treatment phase.

Outcome measures

Outcome measures
Measure
SM-13496 (Lurasidone HCl) 40mg
n=150 Participants
SM-13496 40 mg was administered orally once daily.
SM-13496 (Lurasidone HCl) 80mg
n=154 Participants
SM-13496 80 mg was administered orally once daily.
Placebo
n=151 Participants
Placebo was administered orally once daily.
Proportion of Participants With TEAEs Leading to Discontinuation
11 Participants
11 Participants
16 Participants

SECONDARY outcome

Timeframe: From Baseline to 6 weeks

Population: Safety population defined as subjects who receive at least one dose of the study drug in the treatment phase.

Proportion of participants with treatment-emergent adverse events. A serious adverse event was defined as an AE that met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect; Was an important medical event that might jeopardize the patient or might require medical intervention to prevent one of the outcomes listed above.

Outcome measures

Outcome measures
Measure
SM-13496 (Lurasidone HCl) 40mg
n=150 Participants
SM-13496 40 mg was administered orally once daily.
SM-13496 (Lurasidone HCl) 80mg
n=154 Participants
SM-13496 80 mg was administered orally once daily.
Placebo
n=151 Participants
Placebo was administered orally once daily.
Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)
4 Participants
3 Participants
3 Participants

Adverse Events

SM-13496 (Lurasidone HCl) 40mg

Serious events: 4 serious events
Other events: 99 other events
Deaths: 0 deaths

SM-13496 (Lurasidone HCl) 80mg

Serious events: 3 serious events
Other events: 104 other events
Deaths: 0 deaths

Placebo

Serious events: 3 serious events
Other events: 94 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
SM-13496 (Lurasidone HCl) 40mg
n=150 participants at risk
SM-13496 40 mg was administered orally once daily.
SM-13496 (Lurasidone HCl) 80mg
n=154 participants at risk
SM-13496 80 mg was administered orally once daily.
Placebo
n=151 participants at risk
Placebo was administered orally once daily.
Injury, poisoning and procedural complications
Femoral neck fracture
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Anxiety
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Psychotic disorder
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Schizophrenia
2.0%
3/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.9%
3/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.

Other adverse events

Other adverse events
Measure
SM-13496 (Lurasidone HCl) 40mg
n=150 participants at risk
SM-13496 40 mg was administered orally once daily.
SM-13496 (Lurasidone HCl) 80mg
n=154 participants at risk
SM-13496 80 mg was administered orally once daily.
Placebo
n=151 participants at risk
Placebo was administered orally once daily.
Blood and lymphatic system disorders
Eosinophilia
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Cardiac disorders
Bradycardia
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Cardiac disorders
Palpitations
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Ear and labyrinth disorders
Vertigo
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Ear and labyrinth disorders
Ear pain
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Eye disorders
Eye pain
1.3%
2/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Eye disorders
Conjunctival haemorrhage
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Eye disorders
Conjunctivitis
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Eye disorders
Dry eye
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Eye disorders
Eye discharge
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Eye disorders
Eye pruritus
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Eye disorders
Photophobia
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Eye disorders
Conjunctivitis allergic
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Eye disorders
Eye irritation
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Eye disorders
Ocular hyperaemia
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Nausea
7.3%
11/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
7.8%
12/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
4.6%
7/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Constipation
8.7%
13/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
3.2%
5/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
7.9%
12/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Vomiting
6.0%
9/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
5.8%
9/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.0%
3/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Dyspepsia
4.0%
6/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.6%
4/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.6%
4/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Toothache
2.0%
3/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.6%
4/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.0%
3/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Abdominal discomfort
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.6%
4/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.0%
3/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Abdominal pain upper
2.7%
4/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Diarrhoea
2.0%
3/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
3.3%
5/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Abdominal pain
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.9%
3/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.0%
3/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Salivary hypersecretion
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.9%
3/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Cheilitis
1.3%
2/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Dry mouth
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Gastritis
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Mouth ulceration
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Abdominal distension
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Dyskinesia oesophageal
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Gastrooesophageal reflux disease
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Gingival pain
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Gingivitis
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Haematemesis
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Haemorrhoidal haemorrhage
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Haemorrhoids
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Ileus
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Stomatitis
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Tooth disorder
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Anal fissure
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Anal haemorrhage
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Anal skin tags
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Dental caries
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Functional gastrointestinal disorder
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Lip dry
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Periodontitis
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Periproctitis
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
General disorders
Chest discomfort
2.0%
3/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
General disorders
Irritability
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
General disorders
Oedema peripheral
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
General disorders
Pyrexia
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.0%
3/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
General disorders
Thirst
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
General disorders
Application site pruritus
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
General disorders
Gait disturbance
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
General disorders
Inflammation
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
General disorders
Discomfort
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Hepatobiliary disorders
Hepatic function abnormal
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Immune system disorders
Seasonal allergy
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Nasopharyngitis
6.0%
9/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
7.1%
11/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
4.6%
7/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Upper respiratory tract infection
2.0%
3/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.9%
3/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Urinary tract infection
1.3%
2/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Cellulitis
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Cystitis
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Gastroenteritis
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Influenza
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Localised infection
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Oral herpes
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Pharyngitis
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Pulpitis dental
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Tinea infection
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Tinea pedis
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Tooth abscess
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Abscess
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Adenoviral conjunctivitis
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Chronic sinusitis
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Gingival infection
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Herpes zoster
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Otitis externa
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Paronychia
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Infections and infestations
Rhinitis
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Injury, poisoning and procedural complications
Arthropod bite
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Injury, poisoning and procedural complications
Excoriation
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Injury, poisoning and procedural complications
Fall
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Injury, poisoning and procedural complications
Road traffic accident
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Injury, poisoning and procedural complications
Tooth avulsion
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Injury, poisoning and procedural complications
Bone fissure
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Injury, poisoning and procedural complications
Contusion
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Injury, poisoning and procedural complications
Ligament sprain
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Injury, poisoning and procedural complications
Soft tissue injury
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Injury, poisoning and procedural complications
Subcutaneous haematoma
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Weight decreased
1.3%
2/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.9%
3/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Alanine aminotransferase increased
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.9%
3/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Aspartate aminotransferase increased
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Blood bilirubin increased
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Blood cholesterol increased
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Blood creatine phosphokinase increased
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Blood triglycerides increased
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Low density lipoprotein increased
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Monocyte count increased
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Protein urine present
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Skin test positive
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
White blood cell count decreased
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Blood lactate dehydrogenase increased
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Blood potassium increased
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Electrocardiogram PR shortened
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Electrocardiogram QT prolonged
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Liver function test abnormal
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Investigations
Urobilinogen urine increased
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Metabolism and nutrition disorders
Decreased appetite
1.3%
2/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.9%
3/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.6%
4/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Metabolism and nutrition disorders
Hyponatraemia
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Metabolism and nutrition disorders
Polydipsia
1.3%
2/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Metabolism and nutrition disorders
Dehydration
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Metabolism and nutrition disorders
Diet refusal
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Metabolism and nutrition disorders
Hyperuricaemia
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Metabolism and nutrition disorders
Hypokalaemia
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Metabolism and nutrition disorders
Diabetes mellitus
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Metabolism and nutrition disorders
Dyslipidaemia
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Metabolism and nutrition disorders
Hyperlipidaemia
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Musculoskeletal and connective tissue disorders
Muscle rigidity
2.0%
3/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
3.2%
5/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Musculoskeletal and connective tissue disorders
Back pain
2.7%
4/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.9%
3/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Musculoskeletal and connective tissue disorders
Arthralgia
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.9%
3/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Musculoskeletal and connective tissue disorders
Myalgia
1.3%
2/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Musculoskeletal and connective tissue disorders
Joint swelling
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Musculoskeletal and connective tissue disorders
Muscle tightness
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Musculoskeletal and connective tissue disorders
Osteoarthropathy
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Musculoskeletal and connective tissue disorders
Pain in extremity
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Musculoskeletal and connective tissue disorders
Fasciitis
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Musculoskeletal and connective tissue disorders
Neck pain
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Musculoskeletal and connective tissue disorders
Torticollis
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Akathisia
7.3%
11/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
10.4%
16/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
3.3%
5/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Headache
9.3%
14/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
3.9%
6/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
7.9%
12/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Somnolence
6.0%
9/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.6%
4/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Tremor
3.3%
5/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
5.2%
8/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.6%
4/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Dystonia
2.7%
4/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
3.9%
6/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Dizziness
1.3%
2/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Dyskinesia
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.9%
3/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Bradykinesia
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Extrapyramidal disorder
2.0%
3/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Dysarthria
1.3%
2/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Parkinsonism
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Poor quality sleep
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Restless legs syndrome
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Syncope
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Tardive dyskinesia
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Tension headache
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Nervous system disorders
Cervicobrachial syndrome
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Anxiety
7.3%
11/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
7.1%
11/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
5.3%
8/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Insomnia
6.7%
10/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
7.1%
11/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
4.0%
6/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Schizophrenia
4.0%
6/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
3.9%
6/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
7.9%
12/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Psychotic disorder
2.0%
3/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.6%
4/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Agitation
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.6%
4/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.0%
3/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Sleep disorder
1.3%
2/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Aggression
1.3%
2/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Intentional self-injury
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Delusion
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Depressed mood
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Hallucination
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Impulse-control disorder
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Persecutory delusion
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Psychiatric symptom
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Restlessness
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Suicidal ideation
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Withdrawal syndrome
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Catatonia
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Depression
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Psychiatric disorders
Self injurious behaviour
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Renal and urinary disorders
Dysuria
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Renal and urinary disorders
Bladder spasm
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Renal and urinary disorders
Urinary retention
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Renal and urinary disorders
Haematuria
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Reproductive system and breast disorders
Dysmenorrhoea
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Reproductive system and breast disorders
Menorrhagia
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Reproductive system and breast disorders
Polymenorrhoea
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
4.0%
6/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Respiratory, thoracic and mediastinal disorders
Cough
2.0%
3/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
2.0%
3/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Respiratory, thoracic and mediastinal disorders
Nasal congestion
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Respiratory, thoracic and mediastinal disorders
Productive cough
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Respiratory, thoracic and mediastinal disorders
Rhinalgia
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Respiratory, thoracic and mediastinal disorders
Nasal polyps
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Respiratory, thoracic and mediastinal disorders
Upper respiratory tract inflammation
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Pruritus
1.3%
2/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.6%
4/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.0%
3/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Urticaria
2.0%
3/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Eczema
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Erythema
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Rash
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Skin hyperpigmentation
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Acne
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Blister
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Dermal cyst
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
1.3%
2/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Dermatitis
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Dermatitis contact
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Dry skin
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Hyperhidrosis
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Hyperkeratosis
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Photosensitivity reaction
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Psoriasis
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Skin erosion
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Skin fissures
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Skin and subcutaneous tissue disorders
Scar pain
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Surgical and medical procedures
Tooth extraction
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Surgical and medical procedures
Wisdom teeth removal
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Vascular disorders
Hypertension
1.3%
2/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
2.6%
4/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Vascular disorders
Hypotension
0.00%
0/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.65%
1/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.66%
1/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
Gastrointestinal disorders
Gastrointestinal disorder
0.67%
1/150 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/154 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.
0.00%
0/151 • From Baseline to 6 weeks
TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase. Patients experiencing multiple AEs are counted once in each category.

Additional Information

Regional Function Head of CNS Research

Clinical Research, Drug Development Division

Phone: +81-3-5159-2519

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place